Glaxo Wellcome Ultiva
Executive Summary
Efficacy supplement for analgesic remifentanil approved Oct. 15. Pediatric use section of labeling now states, "efficacy and safety of Ultiva as an analgesic agent for use in the maintenance of general anesthesia" has been established for pediatric surgery patients aged 1-12 years. "However, Ultiva has not been studied in pediatric patients for use as a postoperative analgesic or as an analgesic component of monitored analgesic care." Glaxo plans to submit neonatal studies in the next few weeks, which if accepted, will provide a pediatric indication and six months added exclusivity
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth